Synergy Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Plecanatide In Irritable Bowel Syndrome With Constipation
7/8/2014 10:50:18 AM
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its lead drug plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). Agreement was reached with the FDA for the plecanatide pivotal phase 3 IBS-C clinical development program that is scheduled to begin in the fourth quarter of this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by